pixyl.ai: Advancing Neurological Care with AI-Powered MRI Analysis

pixyl.ai is a cutting-edge medical technology company transforming neurological diagnostics through AI-driven MRI analysis. Specializing in neuroinflammatory and neurodegenerative disorders, its flagship product Pixyl.Neuro delivers rapid, accurate, and FDA-cleared analysis of brain MR images in under five minutes, significantly improving lesion detection sensitivity by up to 28% and reducing radiology reading time by up to 65%. The platform seamlessly integrates into clinical workflows and supports precision medicine via its PRIMUS initiative, which leverages real-world clinical research data for treatment decision support in multiple sclerosis. With validated applications in multiple sclerosis, traumatic brain injury, and stroke, pixyl.ai combines robust scientific research, trustworthy AI models with uncertainty quantification, and deep collaboration with leading institutions including the European Society of Neuroradiology and Inria. Its upcoming solution, Pixyl.Hepato, promises to expand its impact into liver imaging. Designed for healthcare professionals and researchers, pixyl.ai is a powerful ally in early diagnosis, longitudinal monitoring, and clinical trial tracking.

Key Features:

• Pixyl.Neuro: AI-powered detection and analysis of brain MRI anomalies related to neuroinflammatory and neurodegenerative disorders.
• Pixyl.Neuro.MS: Specialized tool for multiple sclerosis diagnosis and follow-up, quantifying lesion volume and brain atrophy in 4–5 minutes.
• Pixyl.Neuro.BV: Advanced brain volumetry analysis measuring grey matter, white matter, CSF, intracranial volume, and cortical/subcortical structures.
• Lesion Segmentation & Counting: Automated identification, classification, and quantification of white matter hyperintensities based on dissemination in time and space.
• Structured Reporting: Generates diagnostic reports aligned with clinical criteria for MS and stroke.
• Longitudinal Analysis: Tracks changes in brain structures and lesion volumes over time for monitoring disease progression and treatment efficacy.
• PRIMUS Platform: A precision medicine framework for MS using clinical research data for treatment selection and decision support.
• FDA 510(k) Clearance & CE Marking: Certified as a Class IIa medical device, ensuring regulatory compliance and clinical reliability.
• Research-Backed AI: Developed with validation in clinical trials and research studies from institutions like ISMRM and Hospices Civils de Lyon.
• Trustworthy AI: Incorporates uncertainty quantification and conformal volume estimation for transparent, reliable results.
• Seamless Radiology Integration: Designed to fit effortlessly into existing clinical workflows with minimal MRI protocol requirements.

Pricing: pixyl.ai offers a freemium model, providing access to core AI analysis tools with scalable features and advanced capabilities available through subscription tiers for clinical and research institutions.

Conclusion: With its clinically validated, regulatory-approved AI solutions and strong scientific foundation, pixyl.ai is a transformative force in neuroimaging, empowering radiologists and researchers to deliver faster, more accurate diagnoses and personalized care in neurological conditions.